Context: Morphine to treat severe chronic breathlessness might increase adverse events (AEs).
Objectives: We aimed to evaluate the risk of AEs in relation to dose, duration and titration phase of regular, low-dose sustained-release (SR) oral morphine for chronic breathlessness in people with chronic obstructive pulmonary disease (COPD).
Methods: Secondary analysis of a double-blind, randomized, trial of SR morphine titrated to 0-32 mg/day over three weeks in people with COPD and chronic breathlessness. Risk of AEs by morphine or placebo dose, duration and titration phase (initiation, stable dose or up-titration) was analyzed using multivariable generalized estimating equation (GEE) models.
Results: We included 156 people (49% female) of whom 100 (64%) experienced any AE during week 1: 64% of those on 8 mg/morphine/day; 78% on 16 mg/morphine/day; and 48% on placebo. In multivariable analysis, the AE risk was highest the first week of morphine treatment and decreased in week two (adjusted rate ratio [aRR] 0.71; 95% confidence interval (CI) 0.54, 0.94) and week three (aRR 0.49; 95% CI 0.37, 0.67). Over the three weeks, the AE risk was similar between titration phases, and there was no statistically significant trend with higher morphine doses (P-values>0.10). Most AEs did not require treatment discontinuation or dose reduction and resolved by the end of titration.
Conclusion: In people with COPD and severe chronic breathlessness, the risk of AEs was highest during the first week of treatment in a dose-related fashion but did not differ by titration phase or by dose of once-daily SR morphine between 8 and 32 mg/day. Trial registration NCT02720822.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jpainsymman.2025.02.020 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Global prevalence of post-COVID-19 condition: a systematic review and meta-analysis of prospective evidence.
Health Promot Chronic Dis Prev Can
March 2025
Evidence Synthesis and Knowledge Translation Unit, Centre for Surveillance and Applied Research, Health Promotion and Chronic Disease Prevention Branch, Public Health Agency of Canada, Ottawa, Ontario, Canada.
Introduction: We investigated the prevalence of new or persistent manifestations experienced by COVID-19 survivors at 3 or more months after their initial infection, collectively known as post-COVID-19 condition (PCC).
Methods: We searched four electronic databases and major grey literature resources for prospective studies, systematic reviews, authoritative reports and population surveys. A random-effects meta-analysis pooled the prevalence data of 22 symptoms and outcomes.
Incidence, predictors, and outcomes of sepsis in revision total hip arthroplasty (rTHA).
Arch Orthop Trauma Surg
March 2025
Houston Methodist, Houston, USA.
Introduction: Revision total hip arthroplasty (rTHA) is increasingly common, with sepsis being a serious but rare complication. Sepsis rates in rTHA vary widely, and understanding risk factors is crucial for improving outcomes. This study aims to evaluate the incidence of sepsis following rTHA and identify preoperative and intraoperative predictors.
View Article and Find Full Text PDFA mixed-methods pilot study of domiciliary nasal high-flow therapy for breathlessness in people with chronic obstructive pulmonary disease who do not qualify for domiciliary long-term oxygen therapy.
Ther Adv Respir Dis
March 2025
Faculty of Medicine and Health Sciences, University of Melbourne, Parkville, VIC, Australia.
Background: High-flow nasal oxygen (HFNO) therapy delivers humidified, heated air with flow rates of up to 60 L/min with oxygen entrained. HFNO has advantages over conventional oxygen therapy, including precise and reliable fraction of inspired oxygen delivery, therefore is recommended as first-line treatment for people with acute hypoxaemic respiratory failure.
Objectives: This pilot study aimed to determine the feasibility and acceptability of domiciliary nasal high flow (NHF) without entrained oxygen for people with chronic obstructive pulmonary disease (COPD) and severe breathlessness.
[Exposure to cassava, corn and soybean dust and respiratory health among artisanal millers in Lubumbashi (Democratic Republic of the Congo)].
Med Trop Sante Int
December 2024
Institut supérieur des techniques médicales de Lubumbashi (ISTM-Lubumbashi), République démocratique du Congo.
Objectives: The aim of this study was to determine the prevalence of respiratory symptoms, their determinants, and the state of respiratory function in millers exposed to cassava, maize, and soybean dust in Lubumbashi, Democratic Republic of Congo (DRC), compared with a group of unexposed workers.
Methods: A descriptive and analytical cross-sectional study was conducted in 2015 on 288 millers and 118 agents (n = 406) from a security agency (control group) in Lubumbashi, DRC. Participants were examined at their place of work.
Palliative Care in End-Stage Lung Disease.
J Hosp Palliat Care
March 2025
Department of Pulmonary, Allergy, and Critical Care Medicine, Kangdong Sacred Heart Hospital, Hallym University Medical Center, Seoul, Korea.
The prevalence of chronic obstructive pulmonary disease (COPD) is increasing, and the condition is associated with a high mortality rate. For patients with COPD, the reality of a life-limiting illness causing severe breathlessness is often daunting. Unlike cancer, the progression of COPD is less predictable, making its prognosis challenging for clinicians.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!